Pfizer collaborates with BioNTech to develop coronavirus vaccine

By Nikita Chaurasia  Date: 2020-03-17

Pfizer collaborates with BioNTech to develop coronavirus vaccine

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNTech SE, an immunotherapy organization pioneering novel therapies for cancer and other serious diseases, to further this cause.

Sources cite that both the companies have agreed to a LOI (letter of intent) regarding the co-development and distribution of potential mRNA-based vaccines for the treatment of COVID-19. The companies have also inked material transfer and collaboration agreements to facilitating immediate working. 

Mikael Dolsten, President and Chief Scientific Officer, Worldwide Research, Development & Medical, Pfizer, said that the company’s successful and on-going relationship with BioNTech gives both the firms the resiliency to mobilize combined resources with exceptional speed in the face of this global challenge.

Integrating Pfizer’s regulatory, development and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise would strengthen their company’s commitment to combatting this increasing pandemic as soon as possible.

Ugur Sahin, CEO and Co-Founder of BioNTech, said that this global pandemic demands for a worldwide effort. With this collaboration, BioNTech believes that it can fuel efforts to bring a COVID-19 vaccine for treating people across the globe.

Moreover, the two companies expects to leverage several research and development sites, including that in the U.S and Germany, to house the actions identified by the collaboration agreement.

Reliable reports claim that BioNTech and Pfizer are expected to team up quickly and finalize the conditions of the agreement such as financial terms, manufacturing, potential commercialization, and development activities over the next few weeks.

Meanwhile, on March 13, 2020, Pfizer declared a five-point plan calling on the biopharmaceutical companies to join the organization in committing to extraordinary collaboration to tackle COVID-19.

Source Credit - https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...